INTRODUCTION
Monoamine oxidase inhibitors (MAOIs) are now reco gni zed as effective me d ications in th e treatment of major depression ( 1). However, th eir clin ica l use has been limi ted by the ris k of severe h ype rte nsive reactions to oral tyram ine challenge. Prevention of this so-called "cheese effect " requires ad herenc e to diet restrictions that can lead to problems with patient co m p lia nce to MAO Is.
L-deprenyl is a selective MA O-B inhibitor that is reportedl y free of th e "cheese effect" (2) . T his rev iew will discuss the clinical and th eoreti cal impo rtance of thi s interesting drug.
PHARMACOLOGY
In 1968, Johnstone reported multiple forms of th e monoamine oxidase (MAO) enzym e (3). MAO-A, an enzyme inhibited b y the MAO I c1orgyline , is responsible for selectively metabolizing norepinephrine and se ro to n in. MAO-B, selectively inh ib ited b y depren yl, preferentially metabolizes phen yleth ylam ine (PEA) and benzylarnine, with little effect on the MAO-A subs t rates. Dopam ine and tyramine a re metabolized b y both types o f MAO enzymes. The first generation MAOIs (phenelzine and tran ylcypromine) non-sel ecti vel y inhibit MAO-A and MAO-B.
Depren yl (a lso known as d eprenil or se leg iline) is a n irre ve rsibl e MAO-B inhibitor (4) . The levorotatory isomer is thought to be more se lective of MAO-B inhibition and is the form most thoroughly stud ied, so t hat re fere nces to depren yl in this paper refer to l-depren yl unless otherwise specified . At doses that are sel ecti ve for MAO-B inhibition (10-3 0 mg/day), st ud ies of depren yl sho w no e vid ence of h ypertensive rea ctions to 200 mg o f ingested tyramine , a co nsidera bly larger amount than found in th e usual di et (5) . Dosages of great er than 30 mg/day of depren ylleads to partial MAO-A inhibition , b u t ne ve r to th e ex te nt of th e non-selective MAO Is.
T he mechanism for d epren yl' s lack o f cheese e ffec t ma y be that, d espite the total MAO-B inhibition , th ere continues to be substantial tyr amine d eam inatio n by intestinal MAO (7), which is predominantly MAO-A (6). Dopam ine in the human brain is metabolized mostly by MAO-B (8), a n d platelet MAO is also of the B-type (9) . Platelet MAO-B inhibition has been used as a mea sure of MAO-B inhibition in the brain (10) , but recent work casts doubt on th e co rrelation between platelet and brain MAO activity (11) . A promising ne w techn iq ue to measure in vivo brain MAO activity utilizes positron e m issio n to mography and lie-labeled selective MAOIs (12) .
As expected, deprenyl administration results in a sharp r ise in u rina r y PEA , and this too can be used to measure the degree of central MAO-B inhibit io n . The ingestion of large amounts of PEA also has no significant pressor response in patients taking deprenyl (5) .
Deprenyl has other biochemical effects in addition to MAO inhibition . It demonstrates some blockade of norepinephrine and dopamine re up ta ke and inhibition of norepin ephrine release (4). Because d epren yl is metabol ized to methamphetamine and amphetamine in humans (13), it has so me d opami ne releasing properties.
CLINICAL TRIALS

Pa rkinson' s Disease
MAOIs have been used in the treatment of Parkinson 's di sea se in conjunction with L-dopa/carbidopa . However, their use has again been limited due to the disabling side effects of hypotension and tyramine crises.
The clinical efficacy of depren yl as an adjunct to standard antipa rk inso nia n treatment is well documented (14) . The mechanism of ac tio n is now th oug h t to be inhibition of striatal dopamine oxidation by MAO-B (15 ), th ereby leadin g to increased availability of dopamine, as opposed to a d opami ne rel easing me chanism (ie. by an amphetamine-like action). The dosages used , usuall y 10-20 mg/day, have produced no adverse effects and no h yp ertensive crises (16) . Because deprenyl potentiates the action of t.-dopa , th e dosage of L-dopa ca n often be lowered when deprenyl is sta r ted. Depren yl ma y be o f particul a r ben e fit in the "off" phase of the on-off phenomenon seen in advan ced stages of Parkinson 's disease that is now recognized as part of th e di sease process rather than a tolerance effect to long-term administration o f L-dopa ( 17) . It is a lso more likely to benefit the "benign" forms of Parkinson's dis ea se and is less effective in the malignant subtypes of this disorder.
Long-term deprenyl use in patients with Parkinson's di sease suggest that use of deprenyI may be associated with prolonged life e xpec ta ncy, a n e ffect no t seen in other antiparkinsonian treatments (16 ,18,19) . Depren yl has a lso been shown to prevent the striatal neurotoxicity of MPTP (20) in animal model s of Parkinson's disease, suggesting that it may prevent progression of th e di sease at some level.
Major Depression J EFFERSO N JOUR N A L OF PSYCHI A TR Y
Clorgyline, th e selecti ve MAO-A inhibitor, has been show n to have significant antidepressant activity. Previous double blind st udies fo und it to be as effective as imipramine (21) . However, because clo rgy line a lso has t he cheese effect, it he ld no advantage over previous MAO Is.
Since MAO-B inhibition is free of the ch eese e ffec t, it wou ld be of clinica l interest if MAO-B inhibitors we re effec t ive a n t idep ressant drugs. Early open studies of depren yl showed an antidepressant effect, b u t these studies used higher, non-selective dosages of the MAO-B inhibitor as well as race m ic form s of depreny l (22) . Negative results were obtained in o ne co n trolled study where pargyline, a partially sel ective MAO-B inhibitor, was shown to be significantl y inferior to clo r gyline in th e treatment o f maj or d epressio n (23) .
There are on ly two controlled studies of d epren yl' s efficacy in depression . Mendlewicz and Youdim (24) , in a double blind study of 27 patients with ROC-defined major depression, found a significantly g reater numbe r of pa tients who responded to 15 mg/day of d epren yl ( 10/ 14 pa tients with < 50% of pretreatment Hamilton Rating Scale [H RS J sco re, 7/1 4 patients with < 25% of pretreatment HRS) as compared to placebo (2/ 13 a nd 0/ 13 patients respectively).
In contrast, Mendis et al conducted a double blind tri al o f depren yl versus placebo in 22 patients with " m ild to moderate " unipola r depressio n (25). The y showed no differen ces between 20 m g/da y of d epren yl and placebo in th e Hamilton scores, se lf-rat ing sca les, a nd g loba l cl in ica l rating sca les. Although diagnostic cr iter ia were not sp ecified, this g rou p's exper ience was that sim ilarly diagnosed patients showed a 50% marked response to t ra d itiona l tricyclics co m pa red to the 20 % re sponse of depren yl and placebo reported in this study.
In an o pe n trial of d epren yl, Mann et a l (26) reported th at 16/ 2 5 ROC-defined depressed patients responded to 10-20 mg/day of d epren yl (respo nse = < 50% pretreatment HRS).
Atypical Depression
MAO Is have traditionall y been t ho ugh t to be most effective for so-call ed " a typ ical depressions" (27) , and some evidence e xists th at perha ps depren yl is more effect ive in th is sub-type of depressive illn ess .
Mendlewicz a nd Youdim noted a non-significant tre nd of t he ir depren yl respo nd ers have " aty pica l sym p to ms" (neu rotic, a nx io us a nd somatic features) ( 17) .
Mann e t al in their open stu dy (26) showed a trend (p < 0.10) for more deprenyl responders among " n o nend oge n o us" d epressives as defined by th e Newcastle Scale (10 / 12 non-endogenous vs 6/1 3 e ndogenous). Bot h groups showed significant reduction o f Hamilton scores a fte r 21 da ys of treatment bu t th e non-endogenous group responded a fte r o n ly 7 da ys. T he non-endogenous group also had low er HRS scores ov erall , but it is uncl ear from their data if thi s was statistically significant. Fewer unipolar endogenous d epressives seemed to respond compared to bipolar, but not at statistically significant le vels.
In an open trial of depren yl in atypical d epressives, Quitk in et al (28 ) found that 10/17 responded (m uc h improved or better on th e CG I). Compared to a placebo group in a parallel doubl e-blind study o f phe nel zine-im ip ram ineplacebo, however, t he re was only a trend to superiori ty of d epre nyl (p < 0 . 10). Of the 10 responders, 9 required doses of30 mg/day, whi ch th e investigators felt was perhaps not selective for MAO-B alone.
SUMMARY OF CLI NICAL TRIALS
While it is clea r th at d eprenyl is a n e ffec t ive a nti parkinsonian drug , its a ntidep ressa nt efficacy is still in question. T he two co ntro lled studies sho w co n flict in g results while open stu d ies have been more e ncour aging, particula rl y in the treatment of aty p ical, non-endogenous d epression. It should be no ted that th e two st ud ies sh o wing negati ve results with MAO-B inhi bito rs used depressed patients with "en dogeno us" sym p to ms, a populati on whic h ma y be less responsive to MAOIs (23, 25) . Futu re co n tro lled stud ies shou ld inco r po ra te subtypin g of d epression or co m pa re d epren yl to non-selecti ve MAO Is.
PSYCHOBIOLOGY OF DEPRESSIO N .lf d epren yl is an effecti ve antidepressant, what mi gh t be its mechanism o f action? Sin ce d epren yl is metabolized to methamphetami ne and amphetamine , and becau se depren yl is reported to have a faster o nset of action than o t her MAO Is, o ne might suspect that its antidepressa n t effect is sim p ly due to amphetam ine. L-d eprenyl is presumably metaboli zed to I-a mph e tam ine , wh ich is thought to be less e u p horia-pro d uc ing than its isomer, d -amph etam ine (29) . In Quitkin e t aI' s study (28) , 7/8 patients showing pre-treatm en t d ysphoric resp onses to amphetamine administration resp onded to deprenyl , while o n ly 3/ 7 showing e up hor ia r esponded to d eprenyl. T hus, it may no t be the am p he tamine-lik e ac tion of deprenyl that is responsibl e fo r its antidepressant e ffect. An other interesting findin g was th at no t o n ly did d epren yl increase urina r y PEA , but it a lso significantl y d ecreased urinary MHPG whe n no effect would be e xpe cted (30) . In addition , those patients with th e low est baseli ne MHPG levels appeared to be th e o nes to respond to d epren yl. Thus, d epren yI's antidepressant action ma y be mediated through bioch emical e ffec ts o ther th a n the MAO-B inhibition.
Mendlewi cz an d Youdim (24) fo u nd th at d epren yl res pond ers had a greate r d egree of platelet MAO-B inh ibition wh en co m pared to non-respo nd e rs. Howe ve r, other investigators have show n that inh ibition of g reate r tha n 80 % of platelet MAO-B consistently occurs e ve n with short term adm in istrat io n of 10 mg of depren yl (31).
What if deprenyl is not an effective antidepressant? Knowing that clorgylin e is effective, this could mean that MAO-A inhibition is the essential mech anism fo r the antidepressant effect. This hypothesis has been forwarded b y seve ra l investigators (23, 25) , and is more consistent with the monoamine h ypothesis of depression since norepinephrine and serotonin, the neurotransmitters traditionally linked to the psychobiology of depression, are metabolized b y MAO-A . Some studies show that only higher doses of depren yl are e ffec tive aga ins t depression, when MAO-A may also be inhibited (28) . If MAO-B inh ibitio n was the critical factor, then one would expect lower doses of depren yl, producing almost complete platelet MAO-B inhibition (31), to be equall y effective. O t her investigators have suggested that the antidepressant effect of MAOIs shares the same mechanism as the cheese effect, postulating that th e effect is mediated through enhancement of central norepinephrine release due to trace amounts of tyramine acting on central synapses (25) . CONCLUSION L-deprenyl, a se lective MAO-B inhibitor, is an effective ad junct ive treatment for Parkinson's disease. However, evidence that se lect ive MAO-B inh ibitors are as effective as non-selective MAOIs in the treatment of d epression remains inconclusive, although there is suggestion that deprenyl ma y be effective in "atypical depression. " Deprenyl is not yet commercially availa ble, b ut further studies are warranted because the lack of a cheese effect co nfers a significant advantage over other MAOIs that would make depren yl an im po rtant addition to our antidepressant armamentarium . Furthermore , b y using selective MAO inhibitors such as clorgyline and deprenyl as psychopharmacological probes we can glean further insights into th e ps ychobiol ogy of d epressive disorders.
